These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 35223425)

  • 1. Interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran.
    Oda N; Mitani R; Takata I; Kataoka M
    Respir Med Case Rep; 2022; 36():101618. PubMed ID: 35223425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 mRNA vaccine-related interstitial lung disease: Two case reports and literature review.
    So C; Izumi S; Ishida A; Hirakawa R; Kusaba Y; Hashimoto M; Ishii S; Miyazaki H; Iikura M; Hojo M
    Respirol Case Rep; 2022 Apr; 10(4):e0938. PubMed ID: 35355663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia.
    Alfaleh A; Alkattan A; Radwan N; Elzohri M; Alzaher A; Ibrahim M; Alsalameen E; Alsultan A; Alhabib D; Alshelwah A; Mahmoud N; Sagor K; Alabdulkareem K
    Drugs Ther Perspect; 2022; 38(2):84-92. PubMed ID: 35095267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse reactions to mRNA coronavirus disease 2019 (COVID-19) vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 576 medical staff.
    Hayashi M; Morikawa S; Goto Y; Yoshida T; Kimura Y; Imaizumi K
    Fujita Med J; 2022 Aug; 8(3):79-82. PubMed ID: 35949514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incomplete Subacute Transverse Myelitis Following Vaccination With Pfizer-BioNTech COVID-19 mRNA Vaccine: A Case Report.
    Alabkal J; Rebchuk AD; Lyndon D; Randhawa N
    Cureus; 2021 Dec; 13(12):e20460. PubMed ID: 35070526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial Lung Disease and Transverse Myelitis: A Possible Complication of COVID-19 Vaccine.
    Khan Z; Khattak AA; Rafiq N; Amin A; Abdullah M
    Cureus; 2022 Feb; 14(2):e21875. PubMed ID: 35273846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
    Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
    Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report of transient polymyalgia rheumatica after receiving the first dose of the BNT162b2 mRNA COVID-19 vaccine.
    Matsuzono K; Fujimoto S
    SAGE Open Med Case Rep; 2024; 12():2050313X241235830. PubMed ID: 38444691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune thrombocytopenia associated with COVID-19 mRNA vaccine tozinameran - a clinical case and global pharmacovigilance data.
    Battegay R; Istampoulouoglou I; Holbro A; Buser A; Hirsiger JR; Eckstein J; Berger CT; Koechlin S; Leuppi-Taegtmeyer AB
    Swiss Med Wkly; 2021 Dec; 151():w30084. PubMed ID: 34908388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse reactions and safety profile of the mRNA COVID-19 vaccines among Asian military personnel.
    Tan JTC; Tan C; Teoh J; Wahab MT; Tan GZ; Chin RYZ; Lee A; Mutalib A; Lim PL
    Ann Acad Med Singap; 2021 Nov; 50(11):827-837. PubMed ID: 34877586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report.
    Kong J; Cuevas-Castillo F; Nassar M; Lei CM; Idrees Z; Fix WC; Halverstam C; Mir A; Elbendary A; Mathew A
    J Infect Public Health; 2021 Oct; 14(10):1392-1394. PubMed ID: 34294590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoster meningitis in an immunocompetent young patient post first dose of BNT162b2 mRNA COVID-19 vaccine, a case report.
    Kerr C; O'Neill S; Szucs A; Darmody O; Williamson C; Bannan C; Merry C
    IDCases; 2022; 27():e01452. PubMed ID: 35186672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Self-reported High-Risk Allergy History With Allergy Symptoms After COVID-19 Vaccination.
    Li L; Robinson LB; Patel R; Landman AB; Fu X; Shenoy ES; Hashimoto DM; Banerji A; Wickner PG; Samarakoon U; Mancini CM; Zhang Y; Blumenthal KG
    JAMA Netw Open; 2021 Oct; 4(10):e2131034. PubMed ID: 34698847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports.
    Vutipongsatorn K; Isaacs A; Farah Z
    J Med Case Rep; 2022 Jan; 16(1):57. PubMed ID: 35094715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
    Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
    Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
    AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
    Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
    Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis.
    Shaker M; Phillips E; Blumenthal KG; Abrams EM; Banerji A; Oppenheimer J; Vander Leek TK; Mack DP; Wickner PG; Singer AG; Khan DA; Greenhawt M
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2556-2561. PubMed ID: 33892171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.